Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Olumiant ® (baricitinib) tabletter
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Treatment-Emergent Adverse Events Related to Hyperlipidemia in the Rheumatoid Arthritis Clinical Development Program
7-Study Placebo-Controlled Dataset
The 7-study pooled dataset included patients with RA randomized to BARI 4 mg (N=1142, PYE=471.8) or placebo (N=1215, PYE=450.8) from 3 phase 2 studies and 4 phase 3 studies (RA-BEAM, RA-BUILD, RA-BEACON and RA-BALANCE). Patients in the placebo group could have been taking background MTX or other conventional DMARDs. Evaluation time periods included through
the 12-week placebo-controlled period in phase 2 studies
16 weeks of assigned treatment before any opportunity for rescue therapy in phase 3 studies, and
24 weeks of assigned treatment or until rescue in phase 3 studies.1
Data from BARI 2 mg (N=479, PYE=185.8) is derived from 4 of these studies in which both BARI 2 mg and BARI 4 mg were options during randomization (2 phase 2 studies as well as RA-BUILD and RA-BEACON).1
4-Study Extended Dataset
The extended dataset included patients with RA randomized to BARI 4 mg (N=479, PYE=781.1) or BARI 2 mg (N=479, PYE=774.9) from 2 phase 2 and 2 phase 3 studies (RA-BUILD, RA-BEACON) and 1 long term extension study (RA-BEYOND). The evaluation time periods included randomization through last available observation incorporating extension data through 01 September 2019 unless otherwise specified. Data were censored at rescue or dose change.2
All BARI RA Dataset
The All BARI RA analysis set included 3770 patients with RA who received BARI at a variety of doses from 1 phase 1, 3 phase 2, and 5 phase 3 studies (RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BALANCE). Data includes a long-term extension study (RA-BEYOND) with
13,148 PYE,
median exposure of 4.2 years,
maximum exposure of 8.4 years, and
Results From the 7-Study Placebo-Controlled Dataset
The proportion of patients who reported hyperlipidemia was
3.2% in the BARI 4-mg group (p=.003 vs placebo)
1.3% in the BARI 2-mg group, and
1.3% in the placebo group.2
Furthermore, the proportion of patients who reported hypercholesterolaemia was
3.4% in the BARI 4-mg group (p=.002 vs placebo)
1.9% in the BARI 2-mg group, and
1.5% in the placebo group.2
There were no serious hyperlipidemia events or temporary or permanent discontinuations from study drug due to hyperlipidemia events up to week 24.2
Results From the 4-Study Extended Dataset
In the combined 4-study extended dataset
hyperlipidaemia was reported by
17 (3.5%; EAIR=2.2) patients in the BARI 4-mg group, and
15 (3.1%; EAIR=1.9) patients in the BARI 2-mg group (p=.718 vs BARI 4 mg), and
hypercholesterolaemia was reported by
33 (6.9%; EAIR=4.2) patients in the BARI 4-mg group, and
14 (2.9%; EAIR=1.8) patients in the BARI 2-mg group (p=.005 vs BARI 4 mg).2
Results From the All BARI RA Dataset
In the All BARI RA dataset consisting of 3770 patients treated with BARI with maximum exposure of 8.4 yrs (PYE=13,148), the MedDRA preferred terms of
hyperlipidaemia was reported in 218 patients (5.8%; 1.7 EAIR), and
hypercholesterolaemia was reported in 250 patients (6.6%; 1.9 EAIR).2
None of these events were considered serious; 1 hyperlipidaemia event led to permanent discontinuation of study drug.2
Changes in Lipid Analytes and Lipid Particle Size
Mean Changes in Lipid Analytes From Baseline
The 5-study pooled dataset included patients with RA randomized to BARI 4 mg or placebo from 1 phase 2 study and 4 phase 3 studies (RA-BEAM, RA-BUILD, RA-BEACON and RA-BALANCE). Data includes a long-term extension study (RA-BEYOND) with data through 13 February 2018.2
BARI 2 mg data is pooled from 3 of these studies in which both BARI 2 mg and BARI 4 mg were options during randomization (1 phase 2 study as well as RA-BUILD and RA-BEACON).2
Compared to placebo, treatment with BARI 2 mg and BARI 4 mg was associated with statistically significant percent increases from baseline through week 24 in
LDL-C
HDL-C, and
total cholesterol (p≤.001 for all).2
Compared to placebo, treatment with BARI 4 mg was also associated with statistically significant percent increases from baseline through week 24 in triglycerides (p≤.001).2,5
The lipid elevations plateaued after week 12.2,5
Changes in Lipid Particle Size
In RA-BEAM, the NMR lipoprotein profile revealed similar changes for BARI and ADA treatment groups relative to the placebo group. Compared to placebo, BARI had statistically significant
increases in
total LDL (p≤.05) and large LDL (p≤.001) mean particle number
total HDL (p≤.001) and all subfractions of HDL (p≤.05) mean particle number, and
decreases in small, medium small, and very small LDL (p≤.01 for all) mean particle numbers.5
Compared to placebo, BARI had statistically significant
increases in LDL (p≤.001) and VLDL (p≤.01) mean particle size, and
modest decrease in HDL (p≤.05) mean particle size.5
Effect of Statins in Combination With Baricitinib on Lipid Analytes
The long-term BARI cohort included patients randomized to receive
BARI 4 mg in RA-BEAM, RA-BUILD, and RA-BEACON, and
BARI 2 mg in RA-BUILD and RA-BEACON.5
The dataset also included data from RA-BEYOND which was censored at dose change or rescue.5
In the long-term BARI cohort, 25 patients receiving BARI 2 mg and 58 patients receiving BARI 4 mg initiated statin therapy after starting BARI. The effects of statin therapy were comparable between the BARI groups and placebo group (n=20) for
LDL-C
total cholesterol, and
triglycerides.5
Monitoring and Management
Dose dependent increases in blood lipid parameters were reported in patients treated with baricitinib compared to placebo.6
Elevations in LDL cholesterol decreased to pre- treatment levels in response to statin therapy.6
Lipid parameters should be assessed approximately 12 weeks following initiation of baricitinib therapy and thereafter patients should be managed according to international clinical guidelines for hyperlipidaemia.6
The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.6
Information From the Label
In controlled studies, for up to 16 weeks hypercholesterolaemia was very commonly reported (≥ 1/10) and hypertriglyceridaemia was uncommonly reported (≥ 1/1,000 to < 1/100 ).6
Lipid Elevations
In rheumatoid arthritis clinical studies, baricitinib treatment was associated with dose-dependent increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. There was no change in the LDL/HDL ratio. Elevations were observed at 12 weeks and remained stable thereafter at a higher value than baseline including in the long-term extension study.6
In studies which included both doses, a dose-relationship was observed with increased total cholesterol ≥ 5.17 mmol/L reported in 48.8 %, 34.7 % and 17.8 % of patients up to 16 weeks in the 4 mg, 2 mg and placebo groups, respectively.6
Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy.6
In controlled studies, for up to 16 weeks, the following frequencies were observed for baricitinib 4 mg vs. placebo:
Increased total cholesterol ≥ 5.17 mmol/L:
Rheumatoid Arthritis: 49.1 % vs.15.8 %, respectively
Increased LDL cholesterol ≥ 3.36 mmol/L:
Rheumatoid Arthritis: 33.6 % vs. 10.3 %, respectively
Increased HDL cholesterol ≥ 1.55 mmol/L:
Rheumatoid Arthritis: 42.7 % vs. 13.8 %, respectively
Increased triglycerides ≥ 5.65 mmol/L:
Rheumatoid Arthritis: 0.4 % vs. 0.5 %, respectively.6
1. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020;2(6):E347-E357. https://doi.org/10.1016/S2665-9913(20)30032-1
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis [abstract]. Ann Rheum Dis. 2020;79(suppl 1):638. https://ard.bmj.com/content/79/Suppl_1/642.1
4. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis. Poster presented at: European League Against Rheumatism Virtual Congress; June 3-6, 2020.
5. Taylor PC, Kremer JM, Emery P, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018;77(7):988-995. http://dx.doi.org/10.1136/annrheumdis-2017-212461
6. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
ADA = adalimumab
BARI = baricitinib
DMARD = disease-modifying antirheumatic drug
EAIR = exposure-adjusted incidence rate
HDL = high-density lipoprotein
HDL-C = high-density lipoprotein cholesterol
LDL = low-density lipoprotein
LDL-C = low-density lipoprotein cholesterol
MedDRA = Medical Dictionary for Regulatory Activities
MTX = methotrexate
NMR = nuclear magnetic resonance
PYE = patient-years of exposure
RA = rheumatoid arthritis
VLDL = very low-density lipoprotein
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2020 M05 27